curasan AG

  • WKN: A2YPGM
  • ISIN: DE000A2YPGM4
  • Land: Deutschland

Nachricht vom 12.09.2019 | 11:43

Torben Sorensen new CEO at curasan AG

DGAP-News: curasan AG / Key word(s): Personnel

12.09.2019 / 11:43
The issuer is solely responsible for the content of this announcement.


Torben Sorensen new CEO at curasan AG

Kleinostheim, September 12, 2019 - The supervisory board of curasan AG (DE000A2YPGM4) today has resolved to appoint Mr. Torben Sorensen as the new CEO of the company as of September 16, 2019 until the end of 31 December 2020.

Torben Sorensen will succeed Michael Schlenk, whose contract anyway expires on September 30, 2019, and whose request for early resignation effective as of the end of September 15, 2019 has been accepted by the Supervisory Board today as well.

Torben Sorensen is a Danish citizen currently living and working in Switzerland. He has been a successful, internationally active interim manager for more than 15 years and has reputation as a turnaround specialist in high-tech companies. Torben Sorensen is also active as a venture capital manager and was CEO of a successful dental med-tech company in Sweden

Today's resolutions of the supervisory board were made in its new assembly with Dr. Kurt Berger, Vienna. Dr. Berger is a self-employed lawyer and was appointed by the court as of September 1, 2019 as the successor of Dr. Tomas Kahn, who has resigned from office.

"After an application process with several candidates, the Supervisory Board unanimously decided in favor of Torben Sorensen based on his professional and personal skills", explains Dr. Detlef Wilke, Chairman of the Supervisory Board. "We are convinced that Torben Sorensen has best qualifications to lead the company into a positive operative direction, and to successfully implement a strategic realignment," added Detlef Wilke. "We are delighted that Torben Sorensen is taking on this responsible position and look forward to working together with great confidence."

The leaving CEO Michael Schlenk welcomes the supervisory board's decision and comments:"In my view the supervisory board made a good choice. I wish Torben Sorensen every success in his challenging new task and some good luck to lead the company and its employees into a profitable future!"


Contact curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.



12.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

PREOS Real Estate AG
"7,5%-Wandelanleihe - Jetzt bis 04.12.19 zeichnen!"

- Emissionsvolumen: bis zu 300 Mio. EUR
- Zeichnungsfrist: 11.19. bis 04.12.2019
- ISIN: DE 000A254NA6 / WKN: A254NA
- Börsenesegment: Börse Frankfurt, Open Market
- Stückelung: 1.000 EUR
- Zinssatz (Kupon): 7,5% p.a., jährliche Zahlung
- Laufzeit: 5 Jahre
- Endfälligkeit: 09.12.2024

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Media and Games Invest wächst dynamisch und profitabel

Innerhalb des Konzerns Media and Games Invest sind der wachstumsstarke Game-Publisher gamigo AG sowie Unternehmen aus dem dynamischen Bereich „Digital Media“ gebündelt. Der Wachstumskurs der Gesellschaft soll sowohl auf Basis eines anhaltenden anorganischen Wachstums sowie durch den Ausbau des bestehenden Geschäftes fortgesetzt werden. Im Rahmen unserer Initial-Coverage-Studie haben wir ein Kursziel von 1,90 € je Aktie ermittelt und vergeben das Rating KAUFEN..

News im Fokus

Continental AG: 'Transformation 2019 - 2029': Continental-Aufsichtsrat unterstützt beschleunigten Technologieumstieg

20. November 2019, 13:19

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

EQS Group AG

Original-Research: EQS Group AG (von GSC Research GmbH): Kaufen

21. November 2019